Drug Database
Back to search

Poland· PL-100405521

Steglatro

A ertugliflozin product containing ertugliflozinum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC A10BK04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSteglatroATCA10BK04REGISTER NO.PL-100405521PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ertugliflozinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ertugliflozin is registered in 11 of 19 countries.

Countries holding a registration under ATC A10BK04 (ertugliflozin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search ertugliflozin products by name

Ertugliflozin · ATC A10BK04

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ertugliflozin costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $2.89 in Italy to $4.50 in Switzerland — a ×1.6 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ertugliflozin · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$4.50
  • IT Italy$2.89
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Ertugliflozinum
Manufacturer
Merck Sharp & Dohme B.V.
Country
Poland (PL)
ATC code
A10BK04
ATC class
Ertugliflozin
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    00191778018547
  • gtin
    00191778018554

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

417 interactions on record for ertugliflozin.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ertugliflozin against other medicinesHow interaction checks work

Ertugliflozin · interactions on record

417 records

  • 1 severe
  • 376 moderate
  • 40 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • PapaverineA03AD01moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ertugliflozin in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ertugliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Steglatro
  • Liechtenstein · Steglatro
  • Norway · Steglatro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6bac16d5-d37d-4140-b312-e014118e7df8
GET /v1/drugs/6bac16d5-d37d-4140-b312-e014118e7df8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "5 mg",
  "packaging": "00191778018547 ¦ Rp ¦ EU/1/18/1267/001 ¦ 128070\n14 tabl.\n00191778018554 ¦ Rp ¦ EU/1/18/1267/002 ¦ 128071\n28 tabl.\nRp ¦ EU/1/18/1267/003 ¦ 128072\n30 tabl.\nRp ¦ EU/1/18/1267/004 ¦ 128073\n30 tabl. (1 x 30)\nRp ¦ EU/1/18/1267/005 ¦ 128074\n84 tabl.\nRp ¦ EU/1/18/1267/006 ¦ 128075\n90 tabl.\nRp ¦ EU/1/18/1267/013 ¦ 131663\n98 tabl.",
  "substance": "Ertugliflozinum 5 mg",
  "common_name": "Ertugliflozinum",
  "pl_product_id": "100405521",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about ertugliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console